{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-005014","form_type":"8-K","ticker":"SPRY","cik":"0001671858","company_name":"ARS Pharmaceuticals, Inc.","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.387043+00:00","generated_at":"2026-05-28T03:32:16.696808+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"ARS Pharma reports preliminary Q4 2024 neffy revenue of $6.5M, cash $314M","bullets":["Preliminary neffy net product revenue for Q4 2024 was approximately $6.5 million, total 2024 revenue $7.1 million since launch on Sept 23.","Cash, cash equivalents and short-term investments were $314.0 million as of Dec 31, 2024, sufficient for at least three years.","More than 14,500 neffy two-pack units delivered in Q4 2024; over 3,000 healthcare providers prescribed neffy to date.","Express Scripts added neffy to commercial formularies in Nov 2024; targeting over 80% commercial coverage by Q3 2025.","sNDA for neffy 1 mg (children 15-30 kg) has PDUFA date March 6, 2025; launch expected Q2 2025 if approved."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-005014","json":"https://secwatch.observer/filing/0001193125-25-005014.json","markdown":"https://secwatch.observer/filing/0001193125-25-005014.md","text":"https://secwatch.observer/filing/0001193125-25-005014.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671858/000119312525005014/0001193125-25-005014-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671858/000119312525005014/d910559d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-28T03:32:16.696808+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}